The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis

Journal of Autoimmunity

Volumn 78, Issue , 2017, Pages 46-56

  Lu, Xin ^a,b   Tang, Quan ^b   Lindh, Monica ^b   Dastmalchi, Maryam ^b   Alexanderson, Helene ^b,c   Popovic Silwerfeldt, Karin ^d   Agerberth, Birgitta ^b   Lundberg, Ingrid E ^b   Wick, Cecilia ^b  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

Innate immunity; Interferon; LL 37; Myositis; Systemic lupus erythematosus

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; VITAMIN D; ANTIMICROBIAL CATIONIC PEPTIDE; AUTOANTIBODY; BIOLOGICAL MARKER; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DERMATOMYOSITIS; DISEASE DURATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MUSCLE BIOPSY; NEUTROPHIL; PLASMACYTOID DENDRITIC CELL; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN BLOOD LEVEL; BIOPSY; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; MIDDLE AGED; MUSCLE; PATHOLOGY; SKIN;

ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOANTIBODIES; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; DERMATOMYOSITIS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; MALE; MIDDLE AGED; MUSCLES; NEUTROPHILS; POLYMYOSITIS; SKIN;

EID: 85008226072     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.12.003     Document Type: Article

References (59)

1. [1] Rider, L.G., Miller, F.W., Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305 (2011), 183–190.
2. [2] Arahata, K., Engel, A.G., Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16 (1984), 193–208.
3. [3] Greenberg, S.A., Pinkus, J.L., Pinkus, G.S., Burleson, T., Sanoudou, D., Tawil, R., Barohn, R.J., Saperstein, D.S., Briemberg, H.R., Ericsson, M., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57 (2005), 664–678.
4. [4] Baechler, E.C., Bilgic, H., Reed, A.M., Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res. Ther., 13, 2011, 249.
5. [5] Wenzel, J., Scheler, M., Bieber, T., Tuting, T., Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br. J. Dermatol., 153, 2005 462–463; author reply 463–464.
6. [6] Isenberg, D.A., Rowe, D., Shearer, M., Novick, D., Beverley, P.C., Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin. Exp. Immunol. 63 (1986), 450–458.
7. [7] Wenzel, J., Schmidt, R., Proelss, J., Zahn, S., Bieber, T., Tuting, T., Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 31 (2006), 576–582.
8. [8] Eloranta, M.L., Barbasso Helmers, S., Ulfgren, A.K., Ronnblom, L., Alm, G.V., Lundberg, I.E., A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 56 (2007), 3112–3124.
9. [9] Lopez de Padilla, C.M., Vallejo, A.N., McNallan, K.T., Vehe, R., Smith, S.A., Dietz, A.B., Vuk-Pavlovic, S., Reed, A.M., Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 56 (2007), 1658–1668.
10. [10] Shrestha, S., Wershil, B., Sarwark, J.F., Niewold, T.B., Philipp, T., Pachman, L.M., Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 62 (2010), 2813–2822.
11. [11] Krystufkova, O., Barbasso Helmers, S., Venalis, P., Malmstrom, V., Lindroos, E., Vencovsky, J., Lundberg, I.E., Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res. Ther., 16, 2014, 454.
12. [12] Lovgren, T., Eloranta, M.L., Bave, U., Alm, G.V., Ronnblom, L., Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50 (2004), 1861–1872.
13. [13] Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature 415 (2002), 389–395.
14. [14] Hilchie, A.L., Wuerth, K., Hancock, R.E., Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat. Chem. Biol. 9 (2013), 761–768.
15. [15] Kahlenberg, J.M., Kaplan, M.J., Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J. Immunol. 191 (2013), 4895–4901.
16. [16] Kai-Larsen, Y., Agerberth, B., The role of the multifunctional peptide LL-37 in host defense. Front. Biosci. 13 (2008), 3760–3767.
17. [17] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292 (1975), 344–347.
18. [18] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292 (1975), 403–407.
19. [19] Betteridge, Z., Gunawardena, H., North, J., Slinn, J., McHugh, N., Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatol. Oxf. 46 (2007), 1005–1008.
20. [20] Dorph, C., Nennesmo, I., Lundberg, I.E., Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J. Rheumatol. 28 (2001), 1591–1599.
21. [21] Ulfgren, A.K., Grundtman, C., Borg, K., Alexanderson, H., Andersson, U., Harris, H.E., Lundberg, I.E., Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 50 (2004), 1586–1594.
22. [22] Englund, P., Lindroos, E., Nennesmo, I., Klareskog, L., Lundberg, I.E., Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am. J. Pathol. 159 (2001), 1263–1273.
23. [23] Azali, P., Barbasso Helmers, S., Kockum, I., Olsson, T., Alfredsson, L., Charles, P.J., Piehl Aulin, K., Lundberg, I.E., Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann. Rheum. Dis. 72 (2013), 512–516.
24. [24] Frohm, M., Agerberth, B., Ahangari, G., Stahle-Backdahl, M., Liden, S., Wigzell, H., Gudmundsson, G.H., The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272 (1997), 15258–15263.
25. [25] Takiguchi, T., Morizane, S., Yamamoto, T., Kajita, A., Ikeda, K., Iwatsuki, K., Cathelicidin antimicrobial peptide LL-37 augments interferon-beta expression and antiviral activity induced by double-stranded RNA in keratinocytes. Br. J. Dermatol. 171 (2014), 492–498.
26. [26] Ong, P.Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R.L., Leung, D.Y., Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347 (2002), 1151–1160.
27. [27] Schittek, B., The antimicrobial skin barrier in patients with atopic dermatitis. Curr. Probl. Dermatol. 41 (2011), 54–67.
28. [28] Gan, L., Miller, F.W., State of the art: what we know about infectious agents and myositis. Curr. Opin. Rheumatol. 23 (2011), 585–594.
29. [29] Stryjewski, M.E., Hall, R.P., Chu, V.H., Kanafani, Z.A., O'Riordan, W.D., Weinstock, M.S., Stienecker, R.S., Streilein, R., Dorschner, R.A., et al. Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis. J. Infect. Dis. 196 (2007), 1425–1430.
30. [30] Sun, C.L., Zhang, F.Z., Li, P., Bi, L.Q., LL-37 expression in the skin in systemic lupus erythematosus. Lupus 20 (2011), 904–911.
31. [31] Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.H., Homey, B., Cao, W., Wang, Y.H., Su, B., Nestle, F.O., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007), 564–U566.
32. [32] Villanueva, E., Yalavarthi, S., Berthier, C.C., Hodgin, J.B., Khandpur, R., Lin, A.M., Rubin, C.J., Zhao, W., Olsen, S.H., Klinker, M., Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187 (2011), 538–552.
33. [33] Zhang, S., Shu, X., Tian, X., Chen, F., Lu, X., Wang, G., Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin. Exp. Immunol. 177 (2014), 134–141.
34. [34] Lande, R., Botti, E., Jandus, C., Dojcinovic, D., Fanelli, G., Conrad, C., Chamilos, G., Feldmeyer, L., Marinari, B., Chon, S., The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun., 5, 2014, 5621.
35. [35] Massa, M., Costouros, N., Mazzoli, F., De Benedetti, F., La Cava, A., Le, T., De Kleer, I., Ravelli, A., Liotta, M., Roord, S., Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 46 (2002), 3015–3025.
36. [36] Pachman, L.M., Lipton, R., Ramsey-Goldman, R., Shamiyeh, E., Abbott, K., Mendez, E.P., Dyer, A., Curdy, D.M., Vogler, L., Reed, A., et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of arthritis and musculoskeletal and skin diseases research registry. Arthritis Rheum. 53 (2005), 166–172.
37. [37] Bene, M.C., Feuillard, J., Jacob, M.C., Groupe d'Etude Immunologique des L., Plasmacytoid dendritic cells: from the plasmacytoid T-cell to type 2 dendritic cells CD4+CD56+ malignancies. Semin. Hematol. 40 (2003), 257–266.
38. [38] Balboni, I., Niewold, T.B., Morgan, G., Limb, C., Eloranta, M.L., Ronnblom, L., Utz, P.J., Pachman, L.M., Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum. 65 (2013), 2424–2429.
39. [39] Ekholm, L., Vosslamber, S., Tjarnlund, A., de Jong, T., Betteridge, Z., McHugh, N., Plestilova, L., Klein, M., Padyukov, L., Voskuyl, A.E., Autoantibody specificities and type I interferon pathway activation in idiopathic inflammatory myopathies. Scand. J. Immunol. 84:2 (2016), 100–109.
40. [40] Mori, M., Pimpinelli, N., Romagnoli, P., Bernacchi, E., Fabbri, P., Giannotti, B., Dendritic cells in cutaneous lupus erythematosus: a clue to the pathogenesis of lesions. Histopathology 24 (1994), 311–321.
41. [41] Blomberg, S., Eloranta, M.L., Magnusson, M., Alm, G.V., Ronnblom, L., Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum. 48 (2003), 2524–2532.
42. [42] Ronnblom, L., Eloranta, M.L., Alm, G.V., Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 36 (2003), 463–472.
43. [43] Meller, S., Winterberg, F., Gilliet, M., Muller, A., Lauceviciute, I., Rieker, J., Neumann, N.J., Kubitza, R., Gombert, M., Bunemann, E., Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 52 (2005), 1504–1516.
44. [44] Migita, K., Miyashita, T., Maeda, Y., Kimura, H., Nakamura, M., Yatsuhashi, H., Ishibashi, H., Eguchi, K., Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus. Clin. Exp. Immunol. 142 (2005), 84–91.
45. [45] Gerl, V., Lischka, A., Panne, D., Grossmann, P., Berthold, R., Hoyer, B.F., Biesen, R., Bruns, A., Alexander, T., Jacobi, A., Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann. Rheum. Dis. 69 (2010), 1370–1377.
46. [46] Krystufkova, O., Vallerskog, T., Helmers, S.B., Mann, H., Putova, I., Belacek, J., Malmstrom, V., Trollmo, C., Vencovsky, J., Lundberg, I.E., Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 68 (2009), 836–843.
47. [47] O'Connor, K.A., Abbott, K.A., Sabin, B., Kuroda, M., Pachman, L.M., MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin. Immunol. 120 (2006), 319–325.
48. [48] Shodell, M., Shah, K., Siegal, F.P., Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 12 (2003), 222–230.
49. [49] Kirou, K.A., Lee, C., George, S., Louca, K., Peterson, M.G., Crow, M.K., Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52 (2005), 1491–1503.
50. [50] Wang, T.T., Nestel, F.P., Bourdeau, V., Nagai, Y., Wang, Q., Liao, J., Tavera-Mendoza, L., Lin, R., Hanrahan, J.W., Mader, S., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173 (2004), 2909–2912.
51. [51] Jeng, L., Yamshchikov, A.V., Judd, S.E., Blumberg, H.M., Martin, G.S., Ziegler, T.R., Tangpricha, V., Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J. Transl. Med., 7, 2009, 28.
52. [52] Adams, J.S., Ren, S., Liu, P.T., Chun, R.F., Lagishetty, V., Gombart, A.F., Borregaard, N., Modin, R.L., Hewison, M., Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 182 (2009), 4289–4295.
53. [53] Liu, P.T., Stenger, S., Li, H., Wenzel, L., Tan, B.H., Krutzik, S.R., Ochoc, M.T., Schauber, J., Wu, K., Meinken, C., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006), 1770–1773.
54. [54] Nursyam, E.W., Amin, Z., Rumende, C.M., The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 38 (2006), 3–5.
55. [55] Aloia, J.F., Li-Ng, M., Re: epidemic influenza and vitamin D. Epidemiol. Infect., 135, 2007 1095–1096;author reply 1097-1098.
56. [56] Aranow, C., Vitamin D and the immune system. J. Investig. Med. 59 (2011), 881–886.
57. [57] Shah, M., Targoff, I.N., Rice, M.M., Miller, F.W., Rider, L.G., Childhood Myositis Heterogeneity Collaborative Study G. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum. 65 (2013), 1934–1941.
58. [58] Mandal, M., Tripathy, R., Panda, A.K., Pattanaik, S.S., Dakua, S., Pradhan, A.K., Chakraborty, S., Ravindran, B., Das, B.K., Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res. Ther., 16, 2014, R49.
59. [59] Baumgarth, N., Bevins, C.L., Autoimmune disease: skin deep but complex. Nature 449 (2007), 551–553.